European Biotech Acquisition Net Income

European Biotech Acquisition (EBAC) currently reports a net income of $3.5M as of December 2022. That compares with $4M in the prior-year period — down 11.8% year over year. That is below the sector sector average of $110M. Use the charts on this page to explore European Biotech Acquisition's net income history and peer comparisons.

European Biotech Acquisition's net income decreased from $4M to $3.5M — a 11.8% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

European Biotech Acquisition's net income of $3.5M is lower than the its sector sector average of $110M. That is roughly 96.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

European Biotech Acquisition reported $3.5M in net income as of December 2022. That compares with $4M in the prior-year period — down 11.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $3.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $110M. From there, open related valuation or income-statement pages for European Biotech Acquisition, and consider following EBAC for alerts when major investors trade the stock.